Recombinant protein maker rEVO Biologics files for a $75 million IPO

By
A A A

rEVO Biologics, which markets a recombinant protein that prevents blood clots in patients with a rare disorder, filed on Wednesday with the SEC to raise up to $75 million in an initial public offering. The company was originally formed as a subsidiary of Genzyme and completed an IPO in 2002, before it was bought by French pharmaceutical company LFB Biotechnologies in 2010.

The Framingham, MA-based company, which was founded in 1993 and booked $33 million in sales for the 12 months ended March 31, 2014, plans to list on the NASDAQ under the symbol RBIO. rEVO Biologics initially filed confidentially on April 11, 2014. Piper Jaffray and Guggenheim Securities are the joint bookrunners on the deal. No pricing terms were disclosed.




The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of The NASDAQ OMX Group, Inc.



This article appears in: News Headlines , IPOs

Referenced Stocks:

Renaissance Capital

Renaissance Capital

More from Renaissance Capital:

Related Videos

Stocks

Referenced

Most Active by Volume

33,110,376
  • $113.99 ▲ 1.77%
25,034,179
    $17.98 unch
24,486,872
  • $7.41 ▲ 2.07%
20,864,535
  • $7.39 ▼ 2.76%
18,600,501
  • $8.30 ▼ 0.36%
17,530,211
  • $8.14 ▲ 3.17%
17,299,208
  • $93.79 ▲ 2.74%
14,669,760
  • $25.78 ▼ 0.19%
As of 12/26/2014, 04:15 PM


Find a Credit Card

Select a credit card product by:
Select an offer:
Search
Data Provided by BankRate.com